Posted by Michael Wonder on 24 Sep 2022
Bausch Health and Glenmark announce the approval of Ryaltris in Canada
23 September 2022 - Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Bausch Health and Glenmark are pleased to announce that Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
